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Abstract
Special AT-rich binding protein-1 (SATB1) is a global chromatin organizer
capable of activating or repressing gene transcription in mice and humans. The
role of SATB1 is pivotal for T-cell development, with SATB1-knockout mice
being neonatally lethal, although the exact mechanism is unknown. Moreover,
SATB1 is dysregulated in T-cell lymphoma and proposed to suppress
transcription of the Pdcd1 gene, encoding the immune checkpoint programmed
cell death protein 1 (PD-1). Thus, SATB1 expression in T-cell subsets across
different tissue compartments in humans is of potential importance for
targeting PD-1. Here, we comprehensively analyzed SATB1 expression across
different human tissues and immune compartments by flow cytometry and
correlated this with PD-1 expression. We investigated SATB1 protein levels in
pediatric and adult donors and assessed expression dynamics of this chromatin
organizer across different immune cell subsets in human organs, as well as in
antigen-specific T cells directed against acute and chronic viral infections. Our
data demonstrate that SATB1 expression in humans is the highest in T-cell
progenitors in the thymus, and then becomes downregulated in mature T cells
in the periphery. Importantly, SATB1 expression in peripheral mature T cells is
not static and follows fine-tuned expression dynamics, which appear to be
tissue- and antigen-dependent. Furthermore, SATB1 expression negatively
correlates with PD-1 expression in virus-specific CD8+ T cells. Our study has
implications for understanding the role of SATB1 in human health and disease
and suggests an approach for modulating PD-1 in T cells, highly relevant to
human malignancies or chronic viral infections.
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INTRODUCTION
Special AT-rich sequence-binding protein 1 (SATB1) is a
chromatin organizer and transcription factor1,2 that
gained increasing interest over recent years as a tumor
marker. In human cancer studies, SATB1 is thought to be
important in promoting tumor growth and invasion,
including breast cancers,3 prostate cancers,4 colorectal
cancers,5,6 or pancreatic cancers.7 Dysregulated SATB1
expression was further linked to the pathogenesis of T-
cell lymphoma.8,9
SATB1 originally was described to be expressed in T-
cell populations, especially in the thymus.1,2,10 Essential
roles of SATB1 in organizing temporal and spatial
expression of genes were shown for T-cell development in
murine thymi after the generation of SATB1-null mice.2
SATB1-null mice had small thymi and spleens and were
fatal by the age of 3 weeks. Thymocyte development was
blocked at the CD4+CD8+ double-positive (DP) stage as
only a few CD4+ and CD8+ single-positive T cells survive
and migrate to the periphery in SATB1-null mice.2
SATB1 is differentially expressed during thymocyte
development and is downregulated in peripheral CD4+ T
cells after thymic exit.11 Although SATB1 has been well-
described in the mouse thymus, less is known about its
expression and role in human thymocytes and peripheral
T-cell subsets. Earlier studies have shown that SATB1
mRNA is predominantly expressed in mouse and human
thymus,1 with lower levels found in the brain and
mammary glands in mice.10 SATB1 transcripts have also
been detected in human testis1 and in cell lines including
Mink lung cells and Jurkat (human) T cells.10 SATB1 was
further shown by whole transcriptome RNA-Seq analysis
to be downregulated in human blood CD4+ regulatory T
cells (Tregs) and by flow cytometry in mouse Tregs.
12
The downregulation of SATB1 in T cells occurred in
murine models of T-cell exhaustion, in which mice were
infected with lymphocytic choriomeningitis virus clone 13
to establish a chronic infection. Microarray data showed
that SATB1 gene expression was downregulated in
exhausted CD8+ T cells during chronic infection
compared to na€ıve CD8+ T cells.13 Exhausted CD8+ T
cells upregulate the immune checkpoint molecule,
programmed cell death protein 1 (PD-1, CD279), leading
to an inhibitory T-cell program when binding to its
ligand PD-L1, as commonly observed during human
malignancies or chronic viral infections. In human
clinical trials, novel antibody-mediated immunotherapies
aimed at blocking PD-1 are currently being used in
patients with chronic conditions such as solid tumors,
including melanoma14-18 (reviewed in [19]) and HIV
patients on anti-retroviral treatment (reviewed in [20]).
The remarkable success of immunotherapies targeting
PD-1 in certain cancers highlights the significance of
reversing T-cell exhaustion.21
A link among SATB1, PD-1 and cancer was found in a
recent study in mice and human samples by Stephen
et al. 2017, demonstrating that SATB1 recruits the
nucleosome remodeling deacetylase complex to the
regulatory regions of the Pdcd1 gene, encoding PD-1, and
thereby preventing its transcription early after CD8+
T-cell activation.22 Furthermore, the addition of
transforming growth factor b (TGF-b), frequently found
in the tumor environment, to human T-cell cultures,
resulted in impairment of TCR-induced SATB1
expression and therefore concomitant increase of PD-1
expression. This was consistent with CD8+CD45RA T
cells isolated from human ovarian cancer and compared
to blood T cells which exhibited lower SATB1 expression,
with higher PD-1 expression in tumor infiltrating cells
than in the periphery.22
SATB1 expression across T-cell subsets from different
tissue compartments in humans might be of importance
for targeting PD-1 in the clinic. Here, we show a
comprehensive analysis of SATB1 expression across
immune compartments from different human tissues by
flow cytometry and correlate this to PD-1 expression. We
investigated SATB1 protein levels in healthy human
tissues obtained from pediatric and adult donors,
including different immune cell subsets from various
human organs. We also examined SATB1 in antigen-
specific T cells against acute and chronic viral infections,
specifically toward the most prominent HLA-A*02:01-
restricted epitope from influenza A virus (IAV) (HLA-
A*02:01-M158–66 (M158))
23,24 and Epstein–Barr virus
(HLA-A*02:01-BMLF1280–288 (GLC)).
25 Our study has
implications for further understanding of differential
SATB1 expression in lymphocytes across healthy
human tissues.
RESULTS
High levels of SATB1 expression in human thymic
T-cell progenitors and downregulation in peripheral
human pediatric T cells
Previous studies in SATB1-null mice demonstrated an
essential role of SATB1 in T-cell development in murine
thymi, with thymocyte development being mainly
blocked at the CD4+CD8+ double positive stage, leading
to a very limited number of single-positive CD4+ and
CD8+ T cells migrating to the periphery.2 Differential
levels of SATB1 expression were measured across various
thymocyte subsets in mice, followed by downregulation
of SATB1 in peripheral CD4+ T cells after thymic exit.11
In the present study, we extended these findings to
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humans and investigated the kinetics of SATB1
expression across different human tissue compartments
and ages.
We utilized a rare cohort of matched human thymi
and peripheral blood mononuclear cells (PBMCs)
obtained from infants and young children aged 0–2 years
(Supplementary table 1). Thymocytes were firstly
analyzed according to their thymic T-cell development
subsets and showed highly abundant CD4+ single-positive
(CD4+ SP) (mean 37.7%, 32.1–42.2%) and CD4+CD8+
double-positive cells (mean 28.9%, 16.6–46.5%), followed
by CD8+ single-positive (CD8+ SP) T-cell progenitors
(mean 14.9%, 5.8–28.1%), and to a lesser extent
CD4CD8 double-negative (DN) early T-cell
progenitors (mean 10.3%, 5.7–19.3%) (Figure 1a). As
expected, CD3CD19+ cells represented a rare thymic B
cell compartment (mean 1.5%, 1.2–2.0%) (Figure 1a).
Thymic T-cell progenitor subsets were intracellularly
stained for SATB1 expression to define SATB1 protein
levels among different thymocyte subsets (Figure 1a).
SATB1 expression was the lowest in thymic CD19+ B
cells (Figure 1a, grey histogram) in comparison to other
thymic progenitor subsets, and thus was used to
normalize geometric mean fluorescence intensity of
SATB1 expression in T-cell subsets across different
experiments. Comparable to studies in mice,11 SATB1
expression was the highest in human DP cells (mean
fold-change of 12.3 over B cells) (Figure 1a, blue) and
CD4+ SP cells (mean fold-change of 8.2 over B cells)
(Figure 1a, red) and lower in CD8+ SP T cells (mean
fold-change of 6.4 over B cells). CD4+ SP cells can be
further divided into immature CD3-CD4+ cells and
CD3+CD4+ cells based on their CD3 expression. The
majority of CD4+ SP cells were CD3+ cells (mean 92.4%),
with higher mean fluorescence intensity levels of SATB1
compared to the immature CD3CD4+ thymocytes
(Figure 1b). Taken together, these findings provide the
first evidence for the hierarchy of SATB1 expression in
human thymocytes: DP CD4+CD8+ > CD4+ SP = CD8+
SP> DN CD4CD8 T cells.
To assess whether the downregulation of SATB1 occurs
in mature human CD4+ and CD8+ T cells following
thymic emigration, as previously shown for mice,11
SATB1 expression was measured in T-cell subsets from
matched pediatric PBMC samples, mainly consisting of
CD4+ T cells (mean 35.8% of lymphocytes), followed by
CD8+ T cells (mean 17.2%), with negligible numbers of
CD4+CD8+ DP T cells (mean 0.6%) (Figure 1c). CD19+
B cells constituted a mean 11.5% of lymphocytes and,
similarly to thymic B cells, expressed very low levels of
SATB1 and thus were used to normalize SATB1
expression levels of T cells in PBMCs. Analysis of SATB1
in pediatric PBMCs showed that both CD4+ SP and
CD8+ SP peripheral T cells had lower levels of SATB1
expression (mean fold-change of 2.2 and 2.4 over B cells,
respectively) compared to thymocytes (Figure 1c).
Although the proportions of CD3+ T cells and CD19+ B
cells of total live lymphocytes did not vary between
matched thymus and pediatric PBMCs (Figure 1d),
SATB1 expression in the peripheral CD4+ and CD8+
T-cell compartments was reduced by almost fourfold in
CD4+ T cells and threefold in CD8+ T cells when
compared to mean fold-changes in the thymus
(Figure 1c, d). Therefore, in humans, SATB1 is
downregulated in both CD4+ and CD8+ T-cell
compartments after exiting from the thymus.
Reduced SATB1 expression in antigen-experienced
adult T cells in blood, spleen and lymph nodes
As the data presented in Figure 1 were obtained from
matched thymus/PBMC samples of pediatric donors up
to 2 years of age, we further investigated SATB1
expression in T and B lymphocyte populations isolated
from the blood (Figure 2a), spleen (Supplementary
figure 1a) and mesenteric lymph nodes (Supplementary
figure 1c) of adult donors (22–60 years, Supplementary
table 1). Additionally, SATB1 expression was analyzed
in CD4+ and CD8+ T cells according to their CD27
and CD45RA expression to differentiate between
CD27+CD45RA+ na€ıve T cells (TN), CD27
+CD45RA
central memory T cells (TCM), CD27
CD45RA effector
memory T cells (TEM) and CD27
CD45RA+ terminal
effector T cells (TTE) (Figure 2c, Supplementary figure
1b and d). Similar to pediatric PBMCs, adult PBMCs
primarily consisted of CD4+ T cells (mean of 36.2% of
live lymphocytes), followed by CD8+ T cells (mean of
21.5%) and then B cells (mean of 12.8%). In alignment
with pediatric thymocytes and PBMCs, there were no
differences in SATB1 mean fluorescence intensity values
between CD4+ and CD8+ T cells in adult PBMCs, but
there was a modest yet significant increase in SATB1
expression levels in both CD4+ and CD8+ T cells when
comparing against CD19+ B cells (mean fold-changes of
1.9 and 2.0 over B cells, respectively) (Figure 2b).
Interestingly, we observed significant differences in
SATB1 expression levels between TN cells and antigen-
experienced TCM, TTE and TEM subsets for both CD4
+ T
cells (TN 2.2, TCM 1.5, TTE n/a and TEM 1.4; mean fold-
change over B cells) and CD8+ T cells (TN 2.3, TCM 1.4,
TTE 1.5 and TEM 1.5; mean fold-change over B cells)
(Figure 2c, right panels). Our results reveal that, in
addition to SATB1 downregulation in T cells exiting the
thymus, there is a hierarchy in SATB1 expression in
mature peripheral blood adult CD4+ and CD8+ T cells,
with SATB1 expression being significantly higher in
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Figure 1. SATB1 expression in humans is downregulated from thymocyte precursors to peripheral T cells. Human thymocytes and PBMCs were
immuno-stained for flow cytometry to measure proportions of CD4+ SP, CD8+ SP, CD4+CD8+ DP and CD4CD8 DN T-cell lineage subsets in
human infant thymi (n = 5) (a) and matched pediatric PBMCs (n = 5) (c). Representative histograms of SATB1 expression for each subset are
shown alongside MFI-fold change over thymic CD19+ B cells, which express low levels of SATB1 (a and c). CD3 expression of CD4+ SP and MFIs
of SATB1 are shown for CD3CD4+ and CD3+CD4+ T-cell progenitors in human thymus (n = 3) (b). Comparisons of CD3+ T cell (including CD4+
and CD8+ subsets) and CD19+ B cell proportions and MFI levels of SATB1 expression between thymus and matching blood samples (d) were
performed using one-way ANOVA or Student’s t-test (*P ≤ 0.05; **P ≤ 0.01). Experiments were performed once for each donor within each
tissue.
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na€ıve T cells compared to antigen experienced effector/
memory-like T cells.
As a next step, we assessed whether SATB1 was further
downregulated following migration of T cells from the
blood to secondary lymphoid tissues such as the spleen
(Figure 2d, e) and lymph nodes (Figure 2f, g). SATB1
expression ratios were marginally lower in splenocytes
compared to PBMCs, with mean fold-changes of 1.3 and
1.4 in splenocyte CD4+ T cells and CD8+ T cells,
respectively, over B cells. Strikingly, there were no
significant differences in SATB1 expression between TN
and effector/memory-like T cells for both CD4+ and
CD8+ T cells in the spleen.
Given SATB1’s differential expression between TN and
effector/memory-like T cells in blood, but not spleen,
SATB1 levels were next investigated in lymph nodes, at
the site of antigen encounter. Here, SATB1 expression
ratios over B cells were moderately higher in CD4+ T
cells (mean of 1.4) and CD8+ T cells (mean fold-changes
of 1.4 and 1.6, respectively), similar to spleen. However,
similar to adult blood but not spleen, slight differences in
SATB1 expression were observed between TN and
effector/memory-like T cells (CD4+ T cells: TN 1.6, TCM
1.1, TTE n/a, and TEM 1.2; CD8
+ T cells: TN 1.7, TCM 1.2,
TTE 1.2, and TEM 1.2; mean fold-change over B cells),
suggesting that the downregulation of SATB1
expression in mature peripheral T-cell subsets was tissue-
dependent and perhaps related to anatomical sites of
antigen encounters.
High SATB1 expression in TN and TCM within human
cord blood
To further explore whether the observed differential
expression of SATB1 between TN and effector/memory-
like T cells occurred predominantly as a result of prior
antigenic exposure, we assessed SATB1 levels in CD4+
and CD8+ T cells in human cord blood, which are
essentially “na€ıve” from external pathogens. Strikingly, we
found significantly higher levels of SATB1 expression in
both CD4+ and CD8+ T cells, with a mean fold-change of
2.9 increase in CD4+ T cells and 3.2-fold increase in
CD8+ T cells, over B cells in human cord blood
(Figure 3a), which were approximately twofold higher
than the changes observed in adult blood and lymph
nodes. As expected, the majority of T cells in human
cord blood were na€ıve, with means of 63.5% and 66.7%
of CD4+ and CD8+ T cells, respectively, displaying a
CD27+CD45RA+ TN phenotype, while the remaining
CD27+ cells were intermediate in their CD45RA
expression (Figure 3b), but they did not fall into distinct
effector/memory-like phenotypes observed in adult blood
and tissues. Nevertheless, SATB1 expression levels were
comparable between the cord blood TN and
CD27+CD45RA/INT T-cell subsets, highlighting that the
downregulation of SATB1 expression between na€ıve and
antigen-experienced T cells in human peripheral blood
and lymph nodes might be a consequence of antigenic
encounters during human life.
Overall, our study across different human tissues and
ages confirms that the na€ıve CD4+ and CD8+ T-cell
compartment is the largest in cord blood and the lowest
in spleen, which harbors the largest TEM reservoir among
all the tissues analyzed (Figure 3c). The greatest
differential SATB1 expression ratios over B cells were
observed in na€ıve T cells with further tissue-specific
SATB1 downregulation in the spleen and lymph nodes
compared to cord and adult blood (Figure 3d). These
results show that SATB1 expression is not only
dependent on antigen experience but can also be
influenced by tissue-specific localization of CD4+ and
CD8+ T cells.
Discordant expression of SATB1 and PD-1 in virus-
specific CD8+ T cells
To further understand whether the observed down-
regulation of SATB1 expression in T cells occurs
following antigenic encounters, we analyzed antigen-
specific CD8+ T cells present in human adult blood for
two immunodominant HLA-A*02:01-restricted epitopes,
influenza-derived M158–66 (GILGFVFTL; referred to as
A2/M158) and EBV-derived BMLF1280–288 (GLCTLVAML;
referred to as A2/GLC). IAV- and EBV-specific CD8+ T
cells were enriched from four HLA-A*02:01-positive
donors using A2/M158- and A2/GLC-tetramers using the
well-established tetramer-associated magnetic enrichment
approach.23-25 Enriched tetramer-positive CD8+ T cells
were then analyzed for T-cell differentiation phenotype
and co-expression of SATB1 and the immune checkpoint
protein PD-1, shown to be pivotal in T-cell exhaustion
following chronic infections or cancer and regulated by
SATB1.22
Data from four donors showed tetramer-positive CD8+
T populations with different mean precursor frequencies,
specific for either IAV-M1 and/or EBV-GLC epitopes
following tetramer-associated magnetic enrichment
(Figure 4a). Enriched A2/M158- and A2/GLC-specific
CD8+ T cells were predominantly CD27CD45RA TEM
cells (Figure 4b). SATB1 expression was compared
between acute (IAV-A2/M158) and chronic (EBV-A2/GLC)
antigen-specific CD8+ T cells from the enriched fraction,
to na€ıve CD8+ TN cells from the unenriched fraction,
which were normalized to SATB1 expression levels in B
cells from the unenriched fractions (Figure 4c). There was
a significant reduction in SATB1 ratios between TN (mean
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Figure 2. Diminished SATB1 expression in human spleen. Representative FACS plots and summarized CD4+, CD8+ CD3+ T cell and CD19+ B cell
populations in adult PBMCs (n = 6) (a) and their respective SATB1 expression as MFI-fold change over B cells in PBMCs (b) spleen (n = 5) (d) and
lymph node (n = 4) (f). CD27+CD45RA+, CD27+CD45RA, CD27CD45RA+, CD27CD45RA T-cell compartments of CD4+ and CD8+ T cells
from adult PBMCs (c) with their respective SATB1 expression as representative histograms and MFI-fold change over CD19+ B cells in PBMCs (c),
spleen (e) and lymph node (g). One-way ANOVA was performed between groups (*P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).
Experiments were performed once for each donor within each tissue.
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fold-change of 2.2) and IAV-A2/M158-specific CD8
+ T
cells (mean fold-change of 1.43), and between TN and
EBV-A2/ GLC-specific CD8+ T cells (mean fold-change of
1.17) (Figure 4c). As PD-1 can be overexpressed in
conditional SATB1-cKO mice22 as well as during chronic
viral infections,26,27 we also examined PD-1 expression and
found that PD-1 expression was highest in antigen-
experienced CD8+ T cells compared to na€ıve CD8+ T cells
(EBV-A2/GLC 9.7, IAV-A2/M158 9.2 and TN 8.1; mean
fold-change over B cells). Interestingly, discordant patterns
of lower SATB1 expression and higher PD-1 expression
was more pronounced in antigen-specific CD8+ T cells
toward the chronic EBV-A2/GLC epitope compared to the
acute IAV-A2/M158 epitope. However, when all the
antigen-specific CD8+ T cell data points were pooled
together, there was a significant negative correlation
between PD-1 and SATB1 expression (Figure 4d), thus
indicating a potential role of SATB1 in regulating PD1
expression in virus-specific CD8+ T cells ex vivo accordant
to previous cancer studies.
Re-inducible SATB1 expression in CD8+ TCMs after
TCR-mediated stimulation
Given the differential SATB1 expression observed between
TN and antigen-experienced T cells, we sought to define
when SATB1 undergoes downregulation following the
antigenic encounter, and whether downregulation of
SATB1 in antigen-experienced T cells was static or re-
inducible and therefore can be upregulated again after re-
stimulation. Previously, activation of human CD4+ and
CD8+ T cells via co-stimulation of the CD3/CD28
pathway was showed to upregulate SATB1, as detected by
western blot and qPCR.22,28 Similarly, SATB1 expression
increases with TCR signaling in murine T cells from
spleen22 and in the thymus.11 However, these studies did
not differentiate between TN and antigen-experienced T
cells, which as shown by our present study, differ greatly
with respect to SATB1 expression.
To measure the dynamics of SATB1 protein levels
following TCR-stimulation, na€ıve TN cells (high SATB1)
and antigen-experienced CD8+ TCM cells (low SATB1) were
bulk-sorted from human PBMCs before labeling with cell
trace violet and then stimulated in vitro with anti-CD3/anti-
CD2822,28 in the presence of IL-2. SATB1 expression was
assessed on day 4 according to cell division and compared to
unstimulated cells treated with IL-2 alone. Histogram peaks
of cell division based on the reduction in cell trace violet
intensity showed that in both CD4+ (Figure 5a, left panels)
and CD8+ T-cell populations (Figure 5b, left panels), TCM
cells had a greater proliferative capacity compared to TN
cells, following TCR stimulation. Interestingly, within both
CD4+ (Figure 5a, middle panels) and CD8+ T-cell
populations, albeit to a lesser extent (Figure 5b, middle
panels), SATB1 expression, measured per division as a fold-
change over undivided cells in the unstimulated group, was
upregulated in TN cells (CD4
+ 5.9, CD8+ 3.9; mean fold-
change over undivided), and even higher in TCM cells (CD4
+
9.8, CD8+ 4.4; mean fold-change over undivided), when
cells had divided at least twice compared to the undivided
cells left with IL-2 only (Figure 5c). Additionally, analysis of
GzmB expression, as an effector CD8+ T cell molecule,
together with SATB1 expression, demonstrated that T cells
with higher GzmB expression also displayed higher SATB1
levels, as compared to T cells not producing GzmB
(Figure 5a, b, right panels).
Temporal changes in SATB1 expression was most
apparent in CD4+ T cells, where SATB1 expression was
elevated early on within the first two divisions in TN cells
and TCM cells, which was then downregulated in later
divisions (Figure 5c). It is also important to note that
CD4+ TCM starting with lower SATB1 expression ex vivo
(data shown in Figure 2) showed higher SATB1
upregulation potential following TCR stimulation, as
compared to TN cells which started with higher baselines
of SATB1 expression, suggesting a maximum threshold
and/or saturation level of SATB1 expression in T cells
(Figure 5c). These data provide further evidence for
differential SATB1 expression dynamics between TN and
TCM in humans, especially for CD4
+ T cells.
Taken together, our results show that SATB1
expression in humans is the highest in T cell progenitors
in the thymus, and then becomes downregulated in T
cells which egress from the thymus. Importantly, SATB1
expression in peripheral mature T cells is not static and
follows fine-tuned expression dynamics, which appear to
be tissue- and antigen-dependent.
Differential SATB1 expression across human organs
We comprehensively compared SATB1 expression in
different CD27/CD45RA CD4+ and CD8+ T-cell subsets
within human blood and tissues for both pediatric and
adult donors, as well as for antigen-experienced CD8+ T
cells, relative to SATB1 expression in B cells within each
population which expresses relatively low levels of SATB1.
We then sought to define the overall distribution of
SATB1 across thymus, lymph nodes, spleens, PBMCs of
cord blood, children and adult donors. Furthermore, we
aimed to determine how SATB1 expression correlates to,
or co-localizes with, PD-1 expression. We performed t-
distributed stochastic neighbor embedding (t-SNE)
analysis across all the different tissues to visualize the
distribution of SATB1 expression in relation to PD-1
expression in different lymphocyte populations
(Figure 6).
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T-SNE data from one representative donor per tissue
showed highly diverse expression patterns of SATB1 in
human thymus during the different T progenitor
developmental stages (Figure 6a). Conversely, SATB1
expression in matching PBMCs from this 1.5-year-old
pediatric donor demonstrated homogeneous expression
across all T-cell populations, and very low levels found only
in CD19+ B cells. Similarly, in human cord blood, SATB1
was mainly expressed in CD3+CD4+ or CD3+CD8+ T cells,
but low in CD19+ B cells (Figure 6b). In contrast, the lymph
nodes showed high levels of SATB1 in smaller clusters
within the B cell population, which was not observed in the
other tissues. In general, high SATB1 expression tended to
co-localize with high CD27 and CD45RA co-expression.
However, the patches of high SATB1 expression did not co-
localize with high PD-1 expression. In alignment with our
earlier analysis of SATB1 expression within the spleen
(Figure 2d, e), t-SNE analysis showed lowest SATB1
expression in spleen with no median fluorescence intensity
differences of SATB1 across CD3+ T cell and CD19+ B cell
compartments, in comparison to all the tissues analyzed.
Interestingly, SATB1 expression was mostly reduced in the
A2/M158- and A2/GLC-antigen-specific CD8
+ T-cell islands
in comparison to other T-cell areas.
Overall, our study shows that SATB1 is not only
important in the thymus as previously thought, but that
Figure 3. SATB1 is highly expressed within T cells in human cord blood. SATB1 expression in CD4+, CD8+ CD3+ T cell and CD19+ B cell
populations in human cord blood (n = 5) (a) and within CD27+CD45RA+, CD27+CD45RA, CD27CD45RA+, CD27CD45RA T cell
compartments of CD4+ and CD8+ T cells (b), as representative histograms and MFI-fold change over CD19+ B cells (bottom panels). Summarized
proportions of CD27+CD45RA+, CD27+CD45RA/INT, CD27CD45RA+, CD27CD45RA T cell compartments of CD4+ and CD8+ T cells across
different human tissues (c) with their respective SATB1 expression as MFI-fold change over CD19+ B cells (d). One-way ANOVA analysis was
performed (*P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). Experiments were performed once for each donor within each tissue.
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it may also has an extended role in the periphery, being
preferentially expressed in less differentiated T-cell subsets
in the blood (especially in young individuals) and lymph
nodes, but not in the spleen. The exact consequences
of its differential expression in the periphery remain to
be elucidated.
DISCUSSION
SATB1 has been shown to be dysregulated in human
T-cell lymphoma.8,9 Given its role in regulating PD-1,22 a
T-cell exhaustion marker,13 SATB1 could be an attractive
molecule to understand PD-1 regulation in current
cancer immunotherapeutic approaches which aim to
reverse T-cell exhaustion by PD-1 blockade. In this study,
we have characterized the level of SATB1 expression in
human T-cell differentiation subsets across different
human tissues in pediatric and adult donors. Our study
is important for understanding common differential
SATB1 expression patterns in healthy individuals. Given
that SATB1 levels are dysregulated in various cancers,
including lymphoma, with a further link to PD-1
regulation, our study can be of relevance to anti-PD-1
immunotherapies in cancer clinical trials.
Here, we comprehensively monitored SATB1
expression over various lymphocyte subsets across
different human lymphoid organs. Aligning with
previous studies in mice,11 our findings verify and
greatly extend the importance of SATB1 beyond the
thymus in humans. In addition to demonstrating high
SATB1 expression levels in human thymus, we also
show that the expression was differentially distributed
across distinct T-cell lineage subsets, with the highest
SATB1 protein expression levels detected in immature
CD4+CD8+ DP thymocytes, followed by CD4+ SP then
CD8+ SP thymocytes, and subsequent downregulation
Figure 4. SATB1 expression is downregulated in antigen-specific CD8+ T cells. Representative FACS plots of CD3+ T cell and CD19+ B cell
populations, and CD4+ and CD8+ T cell populations from human PBMCs (n = 4), followed by overlay FACS plots of unenriched and enriched A2/
M1- and A2/GLC-specific CD8+ T cells, and summarized CD8+ T cell (n = 4) and tetramer+ frequencies (n = 3) per 106 total live lymphocytes (a).
CD27 and CD45RA quadrant expression in unenriched total CD8+ T cells and enriched A2/M1- and A2/GLC-specific CD8+ T cells (b). SATB1 and
PD1 expression levels of unenriched CD8+CD27+CD45RA+ TN were compared to enriched A2/M1- and A2/GLC-specific CD8
+ T cells, normalized
to B cells (c). Pearson correlation of PD-1 versus SATB1 of combined data points from unenriched CD8+CD27+CD45RA+and enriched A2/M1- and
A2/GLC-specific CD8+ T cells (d). One-way ANOVA analysis or Pearson correlation was performed (**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).
Experiments were performed once for each donor within each tissue.
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in mature peripheral blood CD4+ and CD8+ T cells
which exit the thymus.
To date, murine studies have focused on the role of
SATB1 in T-cell lineage studies in the thymus and spleen
using crude flow cytometry, western blot and northern
blot methods. There is also a paucity of evidence
describing SATB1 expression within human lymphocytes,
with only a few reports analyzing bulk populations of T
cells in human cord blood and adult PBMCs.10,12,22,28 In
a seminal study by Stephen et al.,22 SATB1 expression via
Western blotting was compared in non-activated versus
activated human CD4+ and CD8+ T cells, via the CD3/
CD28 TCR stimulation pathway, in the presence or
absence of TGF-b. There was a general upregulation of
SATB1 expression after TCR-stimulation which was
impeded by the presence of TGF-b. In support, Ahlfors
Figure 5. Temporal SATB1 expression following TCR-mediated stimulation and cell division. Representative CTV-histograms and FACS plots of
CTV and GzmB versus SATB1 of CD27+CD45RA+ na€ıve and CD27+CD45RA TCM CD4
+ (n = 4) (a) and CD8+ T cells (n = 3) (b) sorted from
PBMCs and in vitro stimulated for 4 days with anti-CD3/anti-CD28/IL-2 (left panels) or IL-2 alone (right panels) (a and b). Summarized MFI of
SATB1 expression per cell division (Div) in CD27+CD45RA+ na€ıve and CD27+CD45RA TCM CD4
+ (c, top panels) and CD8+ T cells (c, bottom
panels) following TCR-mediated stimulation is shown as fold change over IL-2 alone control in division zero (c, Div 0). One-way ANOVA or
Student0s t-test was performed between groups (*P ≤ 0.05). Experiments were performed once for each donor within each tissue.
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et al.28 showed via Western blot and qPCR that SATB1
was upregulated in CD4+ T cells from human cord blood
following TCR stimulation with anti-CD3/anti-CD28 in
the presence of the T-helper 2 cytokine IL-4.
Furthermore, studies in mice have also shown increases
in SATB1 expression in T cells from spleen22 and
thymus11 following TCR-mediated activation. However,
these studies did not define T cells further into their
differentiation states of na€ıve and antigen-experienced T
cells, whereas our analysis has shown that there are
temporal changes in SATB1 expression with cell division
between na€ıve and effector/memory T cells following
TCR stimulation. However, it is unclear whether
increased resting levels of SATB1 interfere with TN cells
to induce rapid proliferation or whether TCM cells have a
greater capacity to proliferate due to lower SATB1 levels,
or whether it is the different expression dynamics of
SATB1 that play a role in T-cell proliferative capacity
and/or effector function (i.e. expression of granzyme B).
In peripheral tissues, the dysregulation of SATB1
expression is involved in various human cancers. Tumor
stage-dependent downregulation of SATB1 by miR-155
was reported in cutaneous T-cell lymphomas.8
Overexpression of SATB1 has been reported in cutaneous
anaplastic lymphoma driven by the SATB1 promoter
methylation state.9,29 These contrasting findings suggest a
Figure 6. SATB1 expression across age and different human tissues. Representative t-SNE analysis of thymus and matching PBMCs from a child
(a), cord blood, adult LN, spleen, and PBMCs (b). Samples were gated on CD3 (peach), CD3+(grey), CD19+ (rose), CD4+ (light blue), and CD8+
(black) populations. CD4+ and CD8+ T-cell populations in (b) were further analyzed into CD27+CD45RA+ (dark green), CD27+CD45RA (violet),
CD27CD45RA+ (dark blue) and CD27CD45RA (orange) populations. Median fluorescence intensity is displayed for SATB1 (a) and PD-1
expression (a and b) after live/lymphocyte-gated events were down sampled to 25 000 events using the FlowJo software (10.5). For A2/M1 or
A2/GLC-enriched PBMCs samples, live/lymphocyte-gated events of their respective unenriched sample was down-sampled to 25 000 events and
concatenated with the enriched tetramer+ population for t-SNE analysis. Experiments were performed once for each donor within each tissue.
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complex role for SATB1 depending on the
microenvironment and hence a greater level of
understanding is needed surrounding the normal
expression of the chromatin organizer over different
lymphocyte and tissue compartments before we can begin
to understand the consequences of SATB1 dysregulation
in human cancers. Here, we show that SATB1 is highly
expressed in na€ıve cells and downregulated in antigen-
experienced CD8+ T cells, which could be related to the
type of antigen, as we observed minor differences in
SATB1 expression between IAV- and EBV-specific CD8+
T cells. SATB1 expression may be additionally contingent
on the tissue itself where the T cell resides, since
differences observed in SATB1 expression in CD4+ and
CD8+ T cells between adult human spleen and lymph
nodes were found.
In murine studies, SATB1 was shown to act as a
regulator of the Pdcd1 gene22 encoding the immune
checkpoint protein PD-1 in CD8+ T cells, by binding to
the CR-B and CR-C region, two key transcriptional
enhancer sites of the Pdcd1 gene.30 With 98% homology
of SATB1 amino acid sequences between human and
mice31 and similar negative correlation in PD-1
expression upon downregulation of SATB1 in human
CD8+ T cells, makes SATB1 a potential target for further
downstream targeting in human malignancies. Here, we
show a potential negative correlation of SATB1 and PD-1
expression over different human tissues, making it more
relevant in combination for treatment in SATB1-
dysregulated human malignancies.
Taken together, our study shows, at a great level of
resolution, that SATB1 expression over different human
tissues naturally undergoes fine-tuned differential
expression levels and likely decreases from infants to
adults, such as from CD27+CD45RA+ na€ıve T cells to
IAV- and EBV-antigen experienced CD8+ T cells. Our
findings can inform studies addressing PD-1 regulation
by SATB1 and thus are relevant to human malignancies
or chronic viral infections.
METHODS
Human blood and tissue samples
Young human thymi and matching peripheral human blood
samples (age 0–2 years, Supplementary table 1) were obtained
from the Royal Children’s Hospital (Victoria, Australia).
Human umbilical cord blood was obtained from the Mercy
Hospital for Women (Victoria, Australia). Buffy packs of
healthy adult donors (mean age 48.3 years, range 22–60) were
obtained from the Australian Red Cross Blood Service
(Victoria, Australia). Peripheral blood mononuclear cells were
isolated by Ficoll-Paque (GE Healthcare, Uppsala, Sweden)
density-gradient purification before cryopreservation. Spleen
(mean age 48.6 years, range 33–68) and mesenteric/pancreatic
lymph nodes (mean age 53.3 years, range 28–68) were obtained
from deceased organ donors procured through DonateLife
(Victoria, Australia) (Supplementary table 1). Human thymi
were meshed through 70 lm cell strainers (Miltenyi Biotec,
Bergisch Gladbach, Germany) into RPMI-1640 (2 mM EDTA,
ThermoFisher Scientific, Waltham, MA, USA) on ice. Spleens
and lymph nodes were finely chopped and enzymatically
digested with type III collagenase (1 mg mL1, Worthington,
Lakewood, NJ, USA) and DNase I (0.5 mg mL1, Roche, Basel,
Switzerland) in RPMI for 45–60 min (37°C/5% CO2) before
meshing through 70 lm cell strainers. Splenic red blood cells
were lysed with RBC lysis solution (0.168 M ammonium
chloride (APS Chemicals Limited, Seven Hills, NSW, Australia),
0.01 mM EDTA, and 12 mM sodium bicarbonate (Sigma-
Aldrich, Darmstadt, Germany) in Baxter water (Baxter
Healthcare, Old Toongabie, NSW, Australia). Isolated
mononuclear cells were cryopreserved before use.
Human ethics
Human experimental work was conducted according to the
Declaration of Helsinki Principles and the Australian National
Health and Medical Research Council (NHMRC) Code of
Practice. Human ethics approvals were obtained by the
University of Melbourne Human Research Ethics Committee
(IDs: 1443389.3 and 1443540); the Royal Children’s Hospital
Human Research Ethics Committee (ID: 24131G); the Mercy
Health Human Research Ethics Committee (ID: R14725); and
the ARCBS Ethics Committee (ID: 2015#8). All blood donors
provided informed written consent for blood donation.
Tissues from deceased organ donors were obtained after
written informed consent from the next of kin.
Flow cytometry and cell sorting
Lymphocytes from human thymi, cord blood, lymph nodes
(mesenteric and pancreatic), spleen and blood samples were
cell surface stained with anti-CD3-AF700 (557943)/anti-CD3-
PE-CF594 (562280), anti-CD19-BV570 (BioLegend, San Diego,
CA, USA; 302236), anti-CD4-APC-H7 (560158)/anti-CD4-
BV650 (563875), anti-CD8-BV421 (BioLegend, 301035)/anti-
CD8-BV650 (563875)/anti-CD8-PerCP-Cy5.5 (565310),
anti-CD27-BV711 (563167), anti-CD45RA-FITC (555488),
anti-PD-1-PE-Cy7 (561272) antibodies (all from BD
Biosciences, San Jose, CA, USA), unless otherwise stated with
their catalogue number in brackets) and LIVE/DEAD (Aqua,
Near-IR, Molecular Probes, Eugene, OR, USA) or 7-amino-
actinomycin D (Sigma-Aldrich, Darmstadt, Germany) on ice
for 30 min in PBS. Human PBMCs were sorted for
CD27+CD45RA+ na€ıve or CD27+CD45RA TCM CD4
+ and
CD8+ T cell populations using FACS Aria III (BD
Biosciences). Alternatively, cells were fixed and permeablized
using the eBioscience Foxp3 staining kit (ThermoFisher
Scientific, Waltham, MA, USA) then intracellularly stained
with anti-SATB1-AF647 (BD Biosciences, 562378) and anti-
GzmB-AF700 (BD Biosciences, 560213). Samples were
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acquired using a BD LSR Fortessa (BD Bioscience) and
analyzed using FlowJo software (V10.4.2 and 10.5, Treestar,
Ashland, OR, USA) and GraphPad Prism (GraphPad Software,
La Jolla, CA, USA, V7.02).
In vitro T-cell stimulation
Sorted na€ıve CD27+CD45RA+ and TCM CD27
+CD45RA CD4+
or CD8+ T cells from human PBMCs were labeled with
CellTrace violet (ThermoFisher Scientific, Waltham, MA, USA)
for 20 min at 37°C, washed, then resuspended in complete
RPMI (cRPMI, Gibco, Carlsbad, CA, USA) media (2 mM
L-glutamine, 1 mM sodium pyruvate, 100 lM non-essential
amino acids, 5 mM HEPES buffer, 55 lM 2-mercaptoethanol,
100 U mL1 penicillin, 100 lg mL1 streptomycin (Gibco),
10% FCS (Bovogen Biologicals, Keilor East, VIC, Australia) at
5 9 104 cells per 1 mL in a 48-well plate pre-coated with anti-
CD3-OKT3 (10 lg mL1), soluble anti-CD28 (2 lg mL1)
(BD Biosciences) and rhIL-2 (10 U mL1) (BD Biosciences) or
rhIL-2 alone. After 4 days of in vitro stimulation, cells were
harvested, counted in 0.2% trypan blue (Gibco) using a
Neubauer-improved hemocytometer (Marienfeld, Lauda-
K€onigshofen, Germany) and stained for flow cytometry.
Tetramer-associated magnetic enrichment
HLA-A*02:01-GILGFVFTL (A2/M158) and HLA-A*02:01/
GLCTLVAML (A2/GLC) monomer (ImmunoID, University
of Melbourne, Melbourne, VIC, Australia) was tetramerized
with streptavidin-phycoerythrin (PE) (BD Biosciences, San
Jose, CA, USA). PBMCs from HLA-A*02:01-expressing
donors were enriched for A2/M158- and A2/GLC-specific
CD8+ T cells using the A2/M158- and A2/GLC-PE
conjugated-tetramers, respectively, followed by magnetic
enrichment as previously described23,24,32 using anti-PE
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
Enriched, unenriched and flow-through samples were then
stained for flow cytometry.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism
software (GraphPad Software, La Jolla, CA, USA, V7.02). A
Student’s t-test or one-way ANOVA was performed for
comparison between two or multiple groups, unless stated
otherwise. Statistical significance, if present, is described in the
figure legend.
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